Carregant...

Denosumab for treating periprosthetic osteolysis; study protocol for a randomized, double-blind, placebo-controlled trial

BACKGROUND: Wear-induced osteolysis is the main factor in reducing the longevity of total hip arthroplasty (THA). The transmembrane Receptor Activator of Nuclear Factor κ B (RANK) and its corresponding ligand RANKL is an important regulator of osteoclast activity and bone resorption and is associate...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Musculoskelet Disord
Autors principals: Sköldenberg, Olof, Rysinska, Agata, Eisler, Thomas, Salemyr, Mats, Bodén, Henrik, Muren, Olle
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2016
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4841945/
https://ncbi.nlm.nih.gov/pubmed/27108405
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12891-016-1036-5
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!